Ignore the Market Fear in Tech with Profitable Software Plays

Software is a high profit-margin business. Companies embracing a recurring revenue model can do even better. But with tech shares looking volatile lately, these companies have been out of favor with the market as part of the tech space. However, strong earnings by software companies point to further profits ahead. These companies will be able to pass on higher costs, and investors who target successful software companies will come out ahead in time. One such name is Adobe (ADBE). The software company ...
Read More
|

Ignore Supply Chain Problems, This Tech Giant Will Come Out Ahead

With a shortage of computer chips and semiconductors, a number of companies have had to warn that they may not be able to produce enough of some goods to meet demand. For some companies, however, that may not be as big of a problem as expected. One such play that may fare well? Apple (AAPL). The company’s steady sales, particularly with its latest iPhone, appear to put it past some of the shortage issues impacting other companies in the tech space. As ...
Read More
|

Rising Dividends Point to Strong Retail Trends Ahead

A number of companies reduced or eliminated dividend payments during the pandemic last year in a move to preserve cash. Now, a few companies are coming back to the table. But a select few firms have not only kept, but are growing their dividends. Two of those plays are in retail. There’s Williams-Sonoma (WSM). Their shares jumped to a new high on news of a higher dividend payout. But another company just announced a bump as well. With its shares declining in ...
Read More
|

Accounting Issues? No Problem for this Beloved Power Company

Shares of Plug Power (PLUG) took a steep dive last week, as the company announced it needed to restate some of its prior years of accounting. However, that hasn’t stopped analysts from looking beyond the short-term fears. They continue to see long-term opportunity. In fact, one analyst from B. Riley cites the old mantra of buying “when there’s blood in the streets,” even though shares only pulled back about 8 percent on the news. While shares are now down just over 50 ...
Read More
|

Commercial Operations This Year Bode Well for this New Tourism Market

There’s high-flying stocks on Wall Street… and then there’s space tourism stocks. Launched just two years ago, Virgin Galactic Holdings (SPCE) has been a popular name with retail investors. And with the company looking to finally launch commercial spaceflights, it’s gotten its highest analyst rating yet with a $50 price tag. That’s about a 50 percent increase from the current price of shares in the low $30s. Year-to-date, shares have run up as high as the $60 range, pulled back to a ...
Read More
|

Cybersecurity Is Here to Stay—Grab This Top Industry Play

While tech names have been out of favor with the markets the past few weeks, many tech companies continue to post impressive earnings and growth numbers. One such niche is in cybersecurity plays. For instance, CrowdStrike (CRWD) posted a 74 percent jump in revenue. The company’s subscription and recurring revenue has now cleared over $1 billion per year. Yet shares are still well off their recent highs That will likely lead to a number of analyst upgrades in the coming days. While ...
Read More
|

Bitcoin Hits and Slips From Record Highs Again, But Traders Flock to Miners

Even with increased volatility, most assets are near all-time highs. That includes the Dow and S&P 500, and the Nasdaq has nearly recovered from its brief correction. One other area is Bitcoin, which saw a surge in demand just as new stimulus checks started to hit bank accounts. The cryptocurrency surged as high as $61,500 in weekend trading before slipping down during regular market hours. But traders are looking at this milestone and other trends that could fuel another rally. For instance, ...
Read More
|

Obvious Value in a Heavily-Watched Sector

Health care and biotech companies have had some big moves over the past year, but seem to be settling back into the relative underperformance that marked the pre-pandemic era. That’s also applied to pharmaceutical companies too, including those who have developed Covid vaccines. The drug industry’s historically rapid development of a vaccine seems to be no longer impressive. Neither does the likely profits to be had thanks to government support and backing. Case in point? Pfizer (PFE). Shares have shed more than ...
Read More
|